Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders

 
 

Arsanis, Inc. (ASNS) Add to portfolio

Arsanis Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections.

CEO: Rene Russo
http://www.arsanis.com

Recent News + Filings   (All items)

Financial Summary   (All financials)
In millions, except per share itemsDec-31-16Dec-31-15
Revenues17.812.7
            Revenue growth40.3% 
Cost of goods sold24.314.8
Gross profit-6.5-2.1
            Gross margin-36.5%-16.7%
Selling, general and administrative0.00.0
General and administrative0.00.0
EBIT-24.3-14.8
            EBIT margin-136.5%-116.7%
Pre-tax income-23.0-13.2
Income taxes0.00.0
            Tax rate0.0%0.0%
Net income0.00.0
            Net margin-0.1%-0.1%
 
Diluted EPS($44.79)($26.02)
Shares outstanding (diluted)0.00.0
 
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.

Rocket Data Systems, Inc. © 2018 | Contact Us | Data Disclaimer | Terms of Use | Privacy